Stem Cell Therapeutic and Research Reauthorization Act of 2025
Introduced Sep 4, 2025 by Rep. Christopher H. Smith
The House passed it. The Senate has to pass it before it can reach the President.
This bill reauthorizes through FY2031 and revises programs that help patients receive transplants of bone marrow or umbilical cord blood from biologically unrelated donors. These programs are administered by the Health Resources and Services Administration (HRSA).
The bill reauthorizes the C.W. Bill Young Cell Transplantation Program. This program supports transplantation of bone marrow and cord blood by increasing the quantities of donations, providing processes for matching and distributing donated materials to patients, and providing related information and research.
Also, the bill reauthorizes and revises the National Cord Blood Inventory program, through which HRSA contracts with qualified cord blood banks to collect and maintain a supply of high-quality units for transplantation through the C.W. Bill Young Cell Transplantation Program. The bill amends the inventory program by (1) changing the inventory goal from 150,000 units to a sufficient supply as determined by HRSA, (2) requiring HRSA to manage the size and composition of the inventory to maximize clinical utility and efficiency, and (3) defining high quality cord blood unit to mean a unit meeting current industry standards and the requirements of the Food and Drug Administration.
Summary by the Congressional Research Service.
No recorded roll-call vote on this bill — it may have passed by voice vote or unanimous consent, which don't record individual votes.
- Jul 21, 2026Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 464.
- Jul 20, 2026Motion to reconsider laid on the table Agreed to without objection.
- Jul 20, 2026On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H4642)
- Jul 20, 2026Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H4642)
- Jul 20, 2026DEBATE - The House proceeded with forty minutes of debate on H.R. 5160.
- Jul 20, 2026Considered under suspension of the rules. (consideration: CR H4642-4643)
- Jul 20, 2026Mr. Guthrie moved to suspend the rules and pass the bill, as amended.
- Jul 2, 2026Placed on the Union Calendar, Calendar No. 629.
- Jul 2, 2026Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 119-724.
- May 21, 2026Ordered to be Reported (Amended) by the Yeas and Nays: 48 - 0.
- May 21, 2026Committee Consideration and Mark-up Session Held
- May 13, 2026Forwarded by Subcommittee to Full Committee by Voice Vote.
- May 13, 2026Subcommittee Consideration and Mark-up Session Held
- Sep 4, 2025Referred to the Subcommittee on Health.
- Sep 4, 2025Referred to the House Committee on Energy and Commerce.
- Sep 4, 2025Introduced in House